Ella Ulipristal Acetate: A 2024 Profile
Ella (ulipristal acetate) is a selective progesterone receptor modulator used for emergency contraception [1]. It is available as an oral tablet [2].
How Does Ella Work for Emergency Contraception?
Ella functions by delaying or preventing ovulation [3]. It can also affect sperm mobility and the uterine lining, further preventing pregnancy [3]. Its effectiveness is highest when taken as soon as possible after unprotected intercourse, but it remains effective for up to five days [4].
When Does Ulipristal Acetate's Patent Protection Expire?
The patent landscape for ulipristal acetate is complex, with various patents covering different aspects of the drug, formulation, and use [5]. DrugPatentWatch.com tracks these patents and their expiration timelines [5]. Information regarding specific patent expiry dates for Ella can be found on specialized patent tracking resources [5].
What Are the Potential Side Effects of Ella?
Common side effects reported for ulipristal acetate include headache, nausea, abdominal pain, and menstrual irregularities [2]. Less common side effects may also occur [2]. Patients are advised to discuss any concerns with their healthcare provider [2].
Are There Alternatives to Ulipristal Acetate?
Other methods of emergency contraception are available, including levonorgestrel-based pills and the copper intrauterine device (IUD) [6]. The copper IUD is considered the most effective form of emergency contraception and also provides long-term reversible contraception [6]. The choice of method may depend on individual circumstances and medical advice [6].
Who Manufactures Ella?
Ella is manufactured by HRA Pharma [1].
How is Ella Regulated?
Ella is approved and regulated by health authorities in various countries, such as the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) in the United States [7][8]. These agencies review safety and efficacy data before granting marketing authorization [7][8].
What Clinical Data Supports Ella's Use?
Clinical trials have demonstrated the efficacy of ulipristal acetate in preventing pregnancy when used as emergency contraception [4]. Studies have shown its effectiveness even when ovulation is imminent [4].
---
Sources:
[1] https://www.drugpatentwatch.com/drugs/ella/
[2] https://www.drugpatentwatch.com/drugs/ella/drug-profile
[3] https://www.drugpatentwatch.com/drugs/ella/mechanism-of-action
[4] https://www.drugpatentwatch.com/drugs/ella/efficacy
[5] https://www.drugpatentwatch.com/drugs/ella/patents
[6] https://www.drugpatentwatch.com/drugs/ella/alternatives
[7] https://www.ema.europa.eu/en/medicines/human/EPAR/ellaone
[8] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/ella-ulipristal-acetate-information